Actively Recruiting
Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model
Led by Fudan University · Updated on 2024-02-09
166
Participants Needed
2
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A pre-metastatic target organ/primary lesion fusion radiomics model was developed based on the "soil-seed" theory to predict comman tumor metastasis in retrospective settings. To prospectively verify the performance of the target organ/primary lesion fusion radiomics model in predicting tumor metastasis patterns (brain metastasis in lung cancer, liver metastasis in colorectal cancer, lung metastasis in breast cancer), we designed this prospective observational trial.
CONDITIONS
Official Title
Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ECOG performance status score between 0 and 2
- Histological or cytological confirmation of stage III-IV non-small cell lung cancer
- Driver gene testing performed if pathology is adenocarcinoma, including at least EGFR, ALK, ROS1, KRAS, or MET
- Complete baseline imaging data: contrast-enhanced MRI for lung cancer, contrast-enhanced MRI/CT for colorectal cancer, and chest CT for breast cancer
- No metastasis in the target organ on baseline imaging (no brain metastasis for lung cancer, no liver metastasis for colorectal cancer, no lung metastasis for breast cancer)
- Received at least one systemic therapy such as chemotherapy, targeted therapy, or immunotherapy
- Regular follow-up during and after treatment
- Life expectancy of at least 6 months
You will not qualify if you...
- Indeterminate pathological tumor type
- Lack of baseline imaging data before treatment
- Presence of metastasis in the target organ on baseline imaging
- Inability or refusal to undergo regular imaging follow-up
- History of other malignant tumors
- Medical conditions or findings that may interfere with results or increase risk of complications
- Pregnant or lactating women
- Use of long-term medications that may affect disease progression as assessed by a physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
2
Fudan University Shanghai Cancer Center
Shanghai, China
Actively Recruiting
Research Team
X
Xiao Chu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here